AES 005

Drug Profile

AES 005

Alternative Names: AES-005; AVI-005

Latest Information Update: 19 May 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synageva BioPharma
  • Class Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 19 May 2009 Discontinued - Phase-I for Infections in USA (SC)
  • 30 Sep 2008 AES 005 is available for licensing and/or co-development in the USA (http://www.synageva.com)
  • 30 Jun 2005 AVI 005 is available for partnering (http://www.avigenics.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top